ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against ADMA Biologics, Inc. for alleged securities fraud, encouraging investors who suffered losses between August 9, 2024, and March 25, 2026, to participate. The lawsuit claims ADMA made false statements by failing to disclose a related party transaction, using channel stuffing to inflate revenue, and lacking appropriate internal controls. Investors are urged to contact the firm by August 10, 2026, to discuss their rights.
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors in ADMA Biologics, Inc. of a class action securities lawsuit. The lawsuit alleges that ADMA Biologics and its executives failed to disclose material information and made false and misleading statements, including engaging in an undisclosed related-party transaction and using channel stuffing. Investors who suffered losses during the Class Period (August 9, 2024, to March 25, 2026) have until August 10, 2026, to apply for lead plaintiff status.
ADMA UPCOMING DEADLINE: Levi & Korsinsky Alerts ADMA
Levi & Korsinsky, LLP is alerting ADMA Biologics, Inc. stockholders about an upcoming deadline for a securities class action lawsuit. The lawsuit alleges that ADMA engaged in a channel stuffing scheme to falsely report 20% revenue growth for its ASCENIV product, instead of an actual 3% decline, as detailed in a Culper Research report. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek lead plaintiff status.
$ADMA Fraud Notification: ADMA Biologics Sued for Securities Fraud After Channel Stuffing Claims Spark a 29% Stock Drop – Investors Notified to Contact BFA Law by August 10
ADMA Biologics is facing a securities fraud class action lawsuit after its stock dropped significantly following claims of "channel stuffing" by Culper Research. The lawsuit alleges that ADMA's reported 20% growth in 2025 was a result of misleading practices to inflate revenue for its flagship product, ASCENIV, despite waning demand. Investors are encouraged to contact Bleichmar Fonti & Auld LLP by August 10, 2026, to discuss their legal options, as the company's stock fell by a total of 29% in late March 2026.
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA). The lawsuit alleges that ADMA Biologics and its executives failed to disclose material information regarding undisclosed related-party transactions, channel stuffing, and inadequate internal controls, leading to investor losses. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to apply for lead plaintiff status.
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors of ADMA Biologics, Inc. who suffered losses to join a class action lawsuit alleging securities fraud. The lawsuit claims ADMA made false and misleading statements by failing to disclose a related party transaction, using channel stuffing to inflate revenue, and lacking appropriate internal controls. Investors who purchased securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to contact the firm.
ADMA INVESTOR REMINDER: ADMA Biologics, Inc. Investors Have Until August 10, 2026 To Seek Lead Plaintiff Role
Kirby McInerney LLP is reminding investors of ADMA Biologics, Inc. (NASDAQ:ADMA) that they have until August 10, 2026, to apply for lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that ADMA engaged in an undisclosed related party transaction, used channel stuffing to inflate revenue, and lacked adequate internal controls, leading to significant stock price drops following short seller reports and analyst downgrades. Investors who suffered losses during the Class Period of August 9, 2024, through March 25, 2026, are encouraged to contact the firm.
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
The Rosen Law Firm is reminding investors of ADMA Biologics, Inc. (NASDAQ: ADMA) who purchased securities between August 9, 2024, and March 25, 2026, about the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that ADMA Biologics made materially false and misleading statements regarding an undisclosed related party transaction, channel stuffing, and inadequate internal controls. Investors are encouraged to contact the Rosen Law Firm for more information on joining the class action.
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders
Glancy Prongay Wolke & Rotter LLP is reminding investors of ADMA Biologics, Inc. (ADMA) about an upcoming August 10, 2026 deadline to file a lead plaintiff motion in a securities fraud lawsuit. The lawsuit alleges that ADMA made misleading statements and failed to disclose issues like channel stuffing and an undisclosed related party transaction, which led to a significant drop in its stock price after a report by Culper Research. Investors who suffered losses on their ADMA investments during the Class Period (August 9, 2024, to March 25, 2026) are urged to contact the firm.
ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ADMA Biologics, Inc. for purchasers of its publicly traded securities between August 9, 2024, and March 25, 2026. Investors with substantial losses have until Monday, August 10, 2026, to seek appointment as lead plaintiff. The lawsuit alleges that ADMA Biologics made false and misleading statements, including engaging in an undisclosed related-party transaction, using channel stuffing, and lacking adequate internal controls, leading to significant stock price declines.
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders
Glancy Prongay Wolke & Rotter LLP is reminding investors of ADMA Biologics, Inc. (ADMA) about an upcoming August 10, 2026, deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that ADMA made materially false and misleading statements and failed to disclose adverse facts, including engaging in an undisclosed related party transaction and using channel stuffing to inflate revenues, causing its stock price to fall significantly. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, are urged to contact the firm.
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders
Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for shareholders of ADMA Biologics, Inc. (ADMA) who incurred losses, urging them to participate in a securities fraud lawsuit. The lawsuit alleges that ADMA engaged in channel stuffing and undisclosed related-party transactions, leading to materially misleading statements about the company's business and prospects. The deadline to file a lead plaintiff motion is August 10, 2026.
ADMA BIOLOGICS, INC. INVESTORS WITH LOSSES HAVE UNTIL
Bernstein Liebhard LLP reminds investors with losses in ADMA Biologics, Inc. (NASDAQ: ADMA) that they have until August 10, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that ADMA made false and misleading statements, leading to artificially inflated stock prices and investor losses for those who purchased shares between August 9, 2024, and March 25, 2026. Interested investors can contact Bernstein Liebhard LLP to learn more or serve as lead plaintiff.
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
The Rosen Law Firm reminds purchasers of ADMA Biologics, Inc. (NASDAQ: ADMA) securities during the Class Period (August 9, 2024, to March 25, 2026) that the deadline to apply to be lead plaintiff in a securities fraud lawsuit is August 10, 2026. The lawsuit alleges that ADMA Biologics made materially false and misleading statements by engaging in an undisclosed related party transaction, using channel stuffing, and lacking adequate internal controls, leading to investor damages. Investors are encouraged to seek qualified counsel with a strong track record in securities class actions.
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against ADMA Biologics, Inc. for investors who suffered losses. The lawsuit alleges that ADMA engaged in undisclosed related-party transactions, used channel stuffing to inflate revenue, and lacked adequate internal controls, leading to materially misleading statements. Shareholders have until August 10, 2026, to apply to be lead plaintiff.
ADMA Biologics, Inc. Class Action Lawsuit Seeks Recovery
Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics made materially false and misleading statements, including engaging in undisclosed related party transactions and using channel stuffing to inflate revenues, leading to a significant stock price drop. Investors have until August 10, 2026, to file for lead plaintiff status.
ADMA Biologics, Inc. Class Action Lawsuit Seeks Recovery
Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges ADMA Biologics engaged in undisclosed related-party transactions, used channel stuffing to inflate revenues, and lacked adequate internal controls. Investors have until August 10, 2026, to seek lead plaintiff status.
ADMA BIOLOGICS, INC. INVESTORS WITH LOSSES HAVE UNTIL
Bernstein Liebhard LLP reminds investors of ADMA Biologics, Inc. (NASDAQ: ADMA) that they have until August 10, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that ADMA made false and misleading statements about its operations and financial stability between August 9, 2024, and March 25, 2026, leading to artificially inflated stock prices and investor losses. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm.
ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP reminds investors of ADMA Biologics, Inc. (NASDAQ: ADMA) about an upcoming August 10, 2026 deadline to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that ADMA certified effective internal controls while concealing channel stuffing and an undisclosed related-party distributor, despite a research report claiming fictitious revenue growth. Investors who purchased ADMA stock between August 9, 2024, and March 25, 2026, and suffered financial losses, may be eligible to join the lawsuit.
ADMA Biologics, Inc. Notice of August 10, 2026 Application
Kahn Swick & Foti, LLC (KSF) has notified investors of ADMA Biologics, Inc. of a class action securities lawsuit. The lawsuit alleges that ADMA Biologics and its executives failed to disclose material information, including an undisclosed related party transaction, channel stuffing, and inadequate internal controls, which led to investor damages. Investors who suffered losses during the Class Period (August 9, 2024, to March 25, 2026) have until August 10, 2026, to request to be appointed as lead plaintiff.
ADMA Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP is reminding investors of ADMA Biologics (NASDAQ: ADMA) about the August 10, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that ADMA Biologics made false and misleading statements between August 9, 2024, and March 25, 2026, concerning an undisclosed related party transaction, the use of channel stuffing to inflate revenue, and inadequate internal controls. These alleged actions led to a significant drop in ADMA Biologics' stock price after a report by Culper Research exposed the practices.
$ADMA Notification: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action
A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. and its executives. The lawsuit alleges that ADMA engaged in a channel stuffing scheme to inflate its reported 2025 revenue growth, leading to significant stock drops after a report by Culper Research exposed the alleged misconduct. Investors who held ADMA Biologics shares during the relevant period have until August 10, 2026, to seek lead plaintiff status in the case.
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors of ADMA Biologics, Inc. of a class action securities lawsuit with an application deadline of August 10, 2026. The lawsuit alleges that ADMA Biologics and its executives failed to disclose material information and violated federal securities laws, including engaging in undisclosed related party transactions and using channel stuffing. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, and suffered losses are encouraged to contact KSF for more information.
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential
Lowey Dannenberg, P.C. is investigating ADMA Biologics (NASDAQ: ADMA) for potential federal securities law violations. This investigation stems from a report by Culper Research alleging that ADMA Biologics engaged in channel stuffing in 2025 to inflate reported revenue growth. The law firm is seeking investors who suffered losses exceeding $50,000 to participate in the investigation.
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged securities fraud. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, are encouraged to contact the firm by August 10, 2026, to potentially lead the lawsuit. The complaint alleges that ADMA made false and misleading statements, engaged in undisclosed related-party transactions, used channel stuffing, and failed to maintain appropriate internal controls.
ADMA Notification: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action
Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. and its executives. The lawsuit alleges that ADMA Biologics misrepresented revenue growth for 2025 by engaging in a "channel stuffing" scheme to inflate sales of its flagship product, ASCENIV, despite waning demand. This alleged misconduct, revealed by Culper Research, led to a significant drop in ADMA's stock price, causing substantial losses for investors.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Shares of Adma Biologics (ADMA) fell 4.34% despite a broader market upturn, with the S&P 500, Dow, and Nasdaq all gaining. Analysts anticipate ADMA will report earnings of $0.16 per share and revenues of $125.77 million in its upcoming disclosure, representing year-over-year growth. The stock currently holds a Zacks Rank of #5 (Strong Sell) and trades at a Forward P/E of 10.67, which is a discount to its industry average.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA
Rosen Law Firm is encouraging investors of ADMA Biologics, Inc. to secure legal counsel before the August 10, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false and misleading statements about undisclosed related-party transactions, channel stuffing, and a lack of adequate internal controls during the specified Class Period. Investors who purchased ADMA securities during this period may be entitled to compensation.
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice regarding a class action securities lawsuit against ADMA Biologics, Inc. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, are affected. The lawsuit alleges that ADMA Biologics and its executives failed to disclose material information, including an undisclosed related party transaction, channel stuffing, and inadequate internal controls, leading to investor damages. The deadline to apply as a lead plaintiff is August 10, 2026.
ADMA BIOLOGICS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMA
Scott+Scott Attorneys at Law LLP has initiated an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) concerning potential breaches of fiduciary duty by its directors and officers. The investigation follows a short report by Culper Research on March 24, 2026, which alleged channel stuffing and undisclosed related party transactions. Shareholders are encouraged to join the investigation if they own ADMA common stock.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff
Levi & Korsinsky, LLP is reminding shareholders of a lead plaintiff deadline of August 10, 2026, in a securities class action lawsuit against ADMA Biologics, Inc. The lawsuit names Jerrold V. Grossman, co-founder and Vice Chairman, as a defendant for allegedly overseeing false statements in annual reports about revenue recognition and undisclosed related party transactions. The firm alleges that Grossman concealed Genesis BioPharma Services, an entity he controlled, which operated as an undisclosed distributor from ADMA's headquarters.
Investor Announcement: ADMA Biologics Investors are Notified to Contact BFA Law about the Pending Securities Fraud Class Action to Recover Stock Losses
Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ:ADMA) and its executives. The lawsuit alleges that ADMA engaged in a channel stuffing scheme to inflate its reported 2025 growth, leading to significant stock drops after a report by Culper Research. Investors who lost money are encouraged to contact BFA Law by the August 10, 2026, lead plaintiff deadline.
ADMA Biologics, Inc. (ADMA) Class Action Lawsuit Seeks Recovery for Investors; August 10, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (ADMA) on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics made materially false and misleading statements regarding undisclosed related-party transactions, channel stuffing, and inadequate internal controls, leading to a significant stock price drop. Investors have until August 10, 2026, to seek lead plaintiff status in the case.
ADMA Biologics, Inc.(NasdaqGM:ADMA) added to Russell 2000 Growth-Defensive Index
ADMA Biologics, Inc. (NasdaqGM:ADMA) has been added to the Russell 2000 Growth-Defensive Index. The company is a biopharmaceutical firm specializing in plasma-derived biologics for immunodeficient patients and those at risk for infectious diseases, manufacturing three FDA-approved products. This inclusion highlights its market presence and growth potential within the pharmaceuticals sector.
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics,
The Rosen Law Firm is encouraging investors of ADMA Biologics, Inc. to secure counsel before the August 10, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false and misleading statements, including engaging in undisclosed related-party transactions, using channel stuffing, and lacking adequate internal controls. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, may be entitled to compensation.
ADMA Biologics, Inc. Actuals & Estimates (NASDAQ:ADMA)
This article provides an overview of ADMA Biologics Inc. (NASDAQ: ADMA) stock performance, financial estimates, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report dates. The article also provides detailed financial data, including earnings per share, revenue, net income, and EBITDA.
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
ClaimsFiler is reminding investors who suffered losses exceeding $100,000 in ADMA Biologics, Inc. (NasdaqGM: ADMA) to file lead plaintiff applications by August 10, 2026, in a securities class action lawsuit. The lawsuit alleges that ADMA and its executives made false and misleading statements, including engaging in an undisclosed related party transaction, using channel stuffing to inflate revenue, and lacking adequate internal controls, thereby violating federal securities laws. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, are affected.
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is reminding investors of ADMA Biologics, Inc. (ADMA) about an upcoming August 10, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that ADMA made materially false and misleading statements, engaged in an undisclosed related party transaction, used channel stuffing, and lacked adequate internal controls, which led to a significant drop in its stock price after a report by Culper Research revealed these issues. Investors who suffered losses on their ADMA investments during the Class Period (August 9, 2024 to March 25, 2026) are encouraged to contact the law firm.
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP is urging shareholders of ADMA Biologics, Inc. (ADMA) who suffered losses to contact them regarding a securities fraud lawsuit. The lawsuit alleges that ADMA engaged in channel stuffing and an undisclosed related party transaction, leading to misleading revenue reports and a significant stock price drop. The deadline to file a lead plaintiff motion is August 10, 2026.
ADMA Shareholder Alert: ADMA Biologics, Inc. Securities
The Gross Law Firm has issued a shareholder alert for ADMA Biologics, Inc. (NASDAQ: ADMA) due to a securities class action lawsuit. Investors who purchased shares between August 9, 2024, and March 25, 2026, are encouraged to contact the firm by the August 10, 2026, deadline. The complaint alleges that ADMA Biologics made materially false and misleading statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls.
ADMA Biologics, Inc. (ADMA) Investors: August 10, 2026, Deadline in Securities Fraud Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics made materially false and misleading statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls. Investors have until August 10, 2026, to apply for lead plaintiff status.
ADMA Biologics, Inc. Actuals & Estimates (BOATS:ADMA)
This article provides financial actuals and estimates for ADMA Biologics Inc. (ADMA), including analyst price targets, historical stock data, and upcoming earnings reports. It details the company's past earnings and revenue figures, next earnings date, EBITDA, and employee count.
Did You Lose Money on ADMA Biologics, Inc. (ADMA)? Levi & Korsinsky Urges Investors to Act Before August 10, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ADMA Biologics, Inc. (NASDAQ:ADMA) on behalf of investors who suffered losses due to alleged securities fraud between August 9, 2024, and March 25, 2026. The lawsuit claims ADMA Biologics made false statements, engaged in an undisclosed related party transaction, used channel stuffing, and lacked adequate internal controls. Investors who purchased ADMA stock during this period are urged to contact the firm before August 10, 2026, to explore potential recovery.
Price to earnings forward of ADMA Biologics Inc – NASDAQ:ADMA
This page provides information about the price to earnings forward for ADMA Biologics Inc (NASDAQ:ADMA). It appears to be a financial data page from TradingView, focusing on the stock's valuation metrics. The page title itself is the primary content.
Enterprise value to revenue forward of ADMA Biologics Inc – NASDAQ:ADMA
The article provides a financial metric, "Enterprise value to revenue forward," for ADMA Biologics Inc (NASDAQ:ADMA). It appears as a snippet from a financial data platform, likely TradingView, indicating specific financial performance for the biotechnology company. The content itself is very minimal, presenting only the metric and the associated company.
What Are the Allegations Against ADMA Biologics
ADMA Biologics is facing a securities class action investigation after a short-seller report accused the company of "channel stuffing" to inflate its 2025 revenue growth from a real -3% to a reported +20%. The allegations led to a 29% drop in ADMA's stock price, prompting several investor rights law firms to launch investigations into potential securities fraud. While ADMA vehemently denies the claims and analysts generally maintain a "Buy" rating, the company faces significant legal, financial, and reputational risks, with investors closely watching upcoming financial results and the progress of the lawsuits.
INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against ADMA Biologics, Inc. for purchasers of its publicly traded securities between August 9, 2024, and March 25, 2026. Investors with substantial losses have until August 10, 2026, to seek appointment as lead plaintiff. The lawsuit alleges that ADMA Biologics made false or misleading statements, engaged in an undisclosed related party transaction, and used channel stuffing to inflate revenues.
Enterprise value to EBITDA forward of ADMA Biologics Inc – NASDAQ:ADMA
The article presents the Enterprise Value to EBITDA (forward) for ADMA Biologics Inc (NASDAQ:ADMA). While it displays the financial metric, no specific values or changes are provided within the visible content, indicating it's likely a headline for a data table or chart not fully captured. It highlights the company's listing on the Nasdaq Stock Market and is presented as part of TradingView's financial data offerings.
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed a class-action lawsuit against ADMA Biologics, Inc. (NASDAQ:ADMA) alleging that the company made false and misleading statements and engaged in undisclosed related-party transactions and channel stuffing. The lawsuit covers investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, and encourages affected investors to contact the firm by August 10, 2026, to apply for lead plaintiff. This action follows a Culper Research report which led to a significant drop in ADMA's stock price.
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz have announced a securities fraud class action lawsuit against ADMA Biologics, Inc. (ADMA), providing an opportunity for shareholders who incurred losses to lead the legal action. The lawsuit alleges that ADMA engaged in undisclosed related-party transactions, used channel stuffing to manipulate revenue appearance, and lacked adequate internal controls, leading to misleading positive statements about the company. Investors who suffered losses between August 9, 2024, and March 25, 2026, are encouraged to participate before the August 10, 2026, lead plaintiff deadline.
